Showing 3601-3610 of 5154 results for "".
- Biosimilar News: Another Humira Biosimilar Enters US Markethttps://practicaldermatology.com/news/biosimilar-news-another-humira-biosimilar-enters-us-market/2461835/Biocon Biologics Ltd’s HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available in the United States after five years of experience in Europe and two years in Canada. "The launch of HULIO, our biosim
- Merz Aesthetics to Distribute AccuVein’s Visualization Systemhttps://practicaldermatology.com/news/merz-aesthetics-to-distribute-accuveins-visualization-system/2461829/Merz Aesthetics is now the sole authorized distributor of AccuVein’s vein visualization system in the U.S. aesthetics market. A limited initial AccuVein field pilot yielded positive results and significant expansion of both new customers and Merz Aesthetics portfolio adoption. Bas
- Dermatology Around the Globe: First JAK for AD Approved in Indiahttps://practicaldermatology.com/news/dermatology-around-the-globe-first-jak-for-ad-approved-in-india/2461828/Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above experiencing flare-ups of the disease. "The
- Open Enrollment Underway for Phase 2b Trial of Topical AMTX-100 CF3 in ADhttps://practicaldermatology.com/news/open-enrollment-underway-for-phase-2b-trial-of-topical-amtx-100-cf3-in-ad/2461827/Amytrx Therapeutics is enrolling mild to moderate atopic dermatitis patients for its Phase 2b clinical trial of a topical formulation of AMTX-100 CF3. Eligible adults interested in participating or learning more about the trial are encouraged to visit the
- Fifth Piece of Art Added to Boehringer Ingelheim, FIT's DTech Unwearable Collectionhttps://practicaldermatology.com/news/fifth-piece-of-art-added-to-boehringer-ingelheim-fits-dtech-unwearable-collection/2461825/In partnership with the Fashion Institute of Technology's (FIT) DTech Lab and world-renowned designer, Bart Hess, Boehringer Ingelheim is introducing a fifth piece to The Unwearable Collection, an art collection that uses raw materials like paper and glass to uniquely illustrat
- Scleroderma Research Update from Cedars-Sinai’s Kao Autoimmunity Institutehttps://practicaldermatology.com/news/scleroderma-research-update-from-cedars-sinais-kao-autoimmunity-institute/2461818/An estimated 100,000 people in the U.S. are living with scleroderma, an autoimmune disease characterized by thickening and scarring of the skin and vital organs, and the narrowing of the blood vessels which lead to poor circulation. Tthere are about 7,000 to 8,000 new cases every year.
- A Sneak Peek in the AD Pike: Aslan’s Eblasakimab Blocks IL-13Rα1, Inhibits Activation of STAT6https://practicaldermatology.com/news/a-sneak-peek-in-the-ad-pike-aslans-eblasakimab-blocks-il-13ra1-inhibits-activation-of-stat6/2461821/Aslan's eblasakimab, a monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, is showing promise in atopic dermatitis (AD), according to part of a phase 1a, open-label, single ascending dose
- Topline Phase 2b Data: Amlitelimab Performs Well in ADhttps://practicaldermatology.com/news/topline-phase-2b-data-amlitelimab-performs-well-in-ad/2461820/Sanofi’s amlitelimab showed statistically significant improvements in signs and symptoms of moderate-to-severe atopic dermatitis in adults, according to topline Phase 2b data. Amlitelimab is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, a key immune re
- Welcome to Camp Dermhttps://practicaldermatology.com/news/welcome-to-camp-derm/2461816/As kids across the country got ready for summer camp, dermatologists flocked to Brooklyn, NY for their own version of summer camp: Neutrogena’s immersive SkinU Summer Camp. Instead of learning to swim, sliding down a zipline, or playing tennis like kids in camp ofte
- US FDA Nod for Pfizer's Alopecia Drughttps://practicaldermatology.com/news/us-fda-nod-for-pfizers-alopecia-drug/2461814/The US Food and Drug Administration (FDA) approved Litfulo (ritlecitinib, Pfizer Inc) for severe alopecia areata in individuals 12 years of age and older. A kinase inhibitor that targets Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) f